- Home
- GHM vs REPL Comparison
GHM vs REPL Comparison
Compare GHM & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- REPL
- Stock Information
- Founded
- GHM 1936
- REPL 2015
- Country
- GHM United States
- REPL United States
- Employees
- GHM N/A
- REPL N/A
- Industry
- GHM Industrial Machinery/Components
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GHM Industrials
- REPL Health Care
- Exchange
- GHM Nasdaq
- REPL Nasdaq
- Market Cap
- GHM 577.9M
- REPL 547.0M
- IPO Year
- GHM N/A
- REPL 2018
- Fundamental
- Price
- GHM $48.26
- REPL $5.29
- Analyst Decision
- GHM Strong Buy
- REPL Buy
- Analyst Count
- GHM 2
- REPL 10
- Target Price
- GHM $60.00
- REPL $8.25
- AVG Volume (30 Days)
- GHM 122.7K
- REPL 24.0M
- Earning Date
- GHM 08-05-2025
- REPL 08-07-2025
- Dividend Yield
- GHM N/A
- REPL N/A
- EPS Growth
- GHM 184.08
- REPL N/A
- EPS
- GHM 1.26
- REPL N/A
- Revenue
- GHM $215,432,000.00
- REPL N/A
- Revenue This Year
- GHM $13.19
- REPL N/A
- Revenue Next Year
- GHM $8.81
- REPL $194.05
- P/E Ratio
- GHM $38.36
- REPL N/A
- Revenue Growth
- GHM 14.64
- REPL N/A
- 52 Week Low
- GHM $24.78
- REPL $2.68
- 52 Week High
- GHM $58.00
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GHM 41.80
- REPL 41.46
- Support Level
- GHM $46.08
- REPL $5.00
- Resistance Level
- GHM $57.71
- REPL $6.39
- Average True Range (ATR)
- GHM 2.50
- REPL 0.82
- MACD
- GHM -1.12
- REPL -0.01
- Stochastic Oscillator
- GHM 18.29
- REPL 48.42
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.